Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
INTS Intensity Therapeutics
0.0000.0000.00%
Close
01/27 09:30 ET
High
0.000
Open
0.000
Turnover
0.00
Low
0.000
Pre Close
0.000
Volume
0.00
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
No Data
News
Comment
Intensity Therapeutics Lowers Size of Planned IPO to 1.7M Shares From 2.2M
Intensity Therapeutics Lowers Size of Planned IPO to 1.7M Shares From 2.2M
Intensity Therapeutics' INT230-6 Shows Efficacy in Breast Tumor Reduction
Intensity Therapeutics' INT230-6 Shows Potential in Metastatic Sarcoma Survival
Intensity Therapeutics' INT230-6 Increases Survival in Solid Tumor Cancers
Intensity Therapeutics' INT230-6 Demonstrates Increased Survival As Either Monotherapy Or In Combination With Pembrolizumab In Patients With Relapsed, Refractory, Metastatic Solid Tumor Cancers
Patients Receiving INT230-6 Alone (n=64) had a Median Overall Survival (mOS) of 373 DaysData Show INT230-6 is Well Tolerated and Elicits Both Direct Tumor Killing and Immune Activating Effects in a Va
Preview: Intensity Therapeutics, Inc Set To IPO Tomorrow
Intensity Therapeutics, Inc (NASDAQ:INTS) IPO will take place October, 21 on the NASDAQ exchange under the ticker INTS. The company is offering shares at an expected price between $4.00 and $5.00 per
Intensity Therapeutics 2.222M Share IPO Price Range $4.00-$5.00
Intensity Therapeutics, Inc To Start Trading Tomorrow
Intensity Therapeutics, Inc (NASDAQ:INTS) IPO will take place October, 14 on the NASDAQ exchange under the ticker INTS. The company is offering shares at an expected price between $4.00 and $5.00 per
Intensity Therapeutics Sees IPO Pricing at $4 to $5 a Share
Intensity Therapeutics Sees IPO Pricing at $4 to $5 a Share
Intensity Therapeutics Applied to List Stock on Nasdaq Capital Market Under Symbol INTS
Intensity Therapeutics Applied to List Stock on Nasdaq Capital Market Under Symbol INTS
Company Overview
More
Intensity Therapeutics, Inc. engages in the operation a biotechnology company which develops novel immune-based therapeutic products for cancer treatment. Its product INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Westport, CT.
CEO： Mr. Lewis H. Bender
Market： NASDAQ
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet